Abiraterone, administered as prodrug abiraterone acetate, is the sole FDA-approved CYP17A1 inhibitor and demonstrates synergistic efficacy when combined with androgen deprivation therapy (ADT) in patients with prostate cancer (Cheong et al. 2020; Wróbel et al. 2023). The gene discussed is CYP17A1; the disease is prostate carcinoma.